News

Dr. Abrahams was a guest speaker at the New York Pain Society’s 2023 Annual Meeting at the Westchester Marriott in Tarrytown, New York. His talk was entitled, “Digitally Transforming Patient Engagement & Data-Driven Medicine.”

The cornerstone of the talk was based on software he developed for Patient Engagement, Outcome & Remote Therapeutic Monitoring. The software product, “DTX”, was recently sanctioned by the FDA as a 513g SaMD or Software as Medical Device. He initially trialed the software in his own practice and collected outcome data on spine patients leading to the submission of multiple abstracts at national meetings.  The tool is useful for managing complications after surgery and incorporates an alert system for adverse events.

In 2022, The Centers for Medicare & Medicaid Services or CMS, approved the use of Remote Therapeutic Monitoring Codes or RTM for patient care. Dr. Abrahams and his team adapted DTX to enable RTM in addition to Outcomes and Patient Engagement. RTM can be used in patients suffering from problems that require treatment from a Physical Therapist, Orthopedic Surgeon, Physiatrist, or Pulmonologist.

The idea for DTX was developed from a need for obtaining patient outcome data without burdening the patient or provider. Any outcome tool requires human interaction and evaluation tools, both of which are costly and time consuming. Dr. Abrahams realized that texting was easiest and removed the need for a downloaded app on your smartphone. Most patient engagement tools have a 5 – 10% success rate for a response; DTX is successful up to 45% of the time with patient responses, thus far greater than the industry standard.

Dr. Abrahams and his team plan to develop the product into a company with trials in Physical Therapy, Orthopedic Surgery, Chronic Care Management, Medical Device and most recently, insurance companies for medical care. The company will be based in White Plains, NY and plan to start sales in 2023.